EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Efficacy of first-line ART regimens based on tenofovir in HIV-infected patients with pre-existing A62V mutation in reverse transcriptase

E N Ozhmegova iD, A I Kuznetsova, A V Lebedev iD, A A Antonova iD, K V Kim iD, Y M Munchak iD, A S Tumanov iD, E V Kazennova iD

Problems of Virology · 2024

DOI: 10.36233/0507-4088-232 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Problems of Virology, 2024. Verfasst von E N Ozhmegova und 7 weiteren Autor:innen. Beteiligte Einrichtung: National Research Center for Epidemiology and Microbiology named after the Honorary Academician N.F. Gamaleya of the Russian Ministry of Health. Hauptthemen laut MEDLINE: Tenofovir, HIV Infections, HIV Reverse Transcriptase, HIV-1. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 21 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

The amino acid substitution A62V in reverse transcriptase was identified as a mutation correlated with virologic failure in patients on first-line therapy including tenofovir (TDF) and tenofovir alafenamide (TAF). A62V is a typically polymorphic mutation in HIV-1 sub-subtype A6, which is the most widespread virus variant in Russia. Materials and methods. The European EuResist (EIDB) database was queried to form two equivalent groups of patients: group 1 ‒ patients with A62V at baseline treated with TDF or TAF on the first-line therapy, group 2 ‒ patients without A62V at baseline treated with TDF or TAF on the first-line therapy. Each group included 23 patients.

Results

There was no statistical difference between the two groups in virologic efficacy in 4, 12, and 24 weeks after the start of antiretroviral therapy (ART) and in the frequency of virologic failures.

Conclusion

This study has some limitations, and the exact role of A62V in the efficacy of the first-line ART based on tenofovir deserves further investigation.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

TenofovirHIV InfectionsHIV Reverse TranscriptaseHIV-1MutationAnti-HIV AgentsHumansMaleFemaleAdultMiddle AgedDrug Resistance, ViralAmino Acid SubstitutionAlanineRussiaAdenineReverse Transcriptase InhibitorsViral Load

Stichwörter der Autor:innen

A62VHIV-1TDF/TAFfirst-line ART regimenreverse transcriptase

Substanzen

TenofovirHIV Reverse TranscriptaseAnti-HIV Agentstenofovir alafenamideAlanineAdenineReverse Transcriptase Inhibitorsreverse transcriptase, Human immunodeficiency virus 1

Autor:innen und Institutionen

  • National Research Center for Epidemiology and Microbiology named after the Honorary Academician N.F. Gamaleya of the Russian Ministry of Health.

ORCID-Profile: E N Ozhmegova, A V Lebedev, A A Antonova, K V Kim, Y M Munchak, A S Tumanov, E V Kazennova

Zitieren

APA

Ozhmegova, E. N., Kuznetsova, A. I., Lebedev, A. V., Antonova, A. A., Kim, K. V., Munchak, Y. M., Tumanov, A. S., & Kazennova, E. V. (2024). Efficacy of first-line ART regimens based on tenofovir in HIV-infected patients with pre-existing A62V mutation in reverse transcriptase. Problems of Virology. https://doi.org/10.36233/0507-4088-232

Vancouver

Ozhmegova EN, Kuznetsova AI, Lebedev AV, Antonova AA, Kim KV, Munchak YM, et al. Efficacy of first-line ART regimens based on tenofovir in HIV-infected patients with pre-existing A62V mutation in reverse transcriptase. Problems of Virology. 2024. doi:10.36233/0507-4088-232

BibTeX
@article{Ozhmegova2024,
  author = {Ozhmegova, E N and Kuznetsova, A I and Lebedev, A V and Antonova, A A and Kim, K V and Munchak, Y M and Tumanov, A S and Kazennova, E V},
  title = {Efficacy of first-line ART regimens based on tenofovir in HIV-infected patients with pre-existing A62V mutation in reverse transcriptase},
  journal = {Problems of Virology},
  year = {2024},
  doi = {10.36233/0507-4088-232}
}
Kostenlos starten →